Lantern Pharma Inc., a Delaware-based company, has announced the entry into an ATM Sales Agreement with ThinkEquity LLC. This agreement, established on July 3, 2025, allows Lantern Pharma to offer and sell up to $15,530,000 in common stock shares. Acting as sales agent or principal, ThinkEquity LLC will facilitate these transactions as specified by Lantern Pharma. The sales are registered under the Securities Act of 1933, following a registration statement declared effective by the SEC in June 2024. The agreement can be terminated by either party with ten days' notice.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017810), on July 03, 2025, and is solely responsible for the information contained therein.